Search for content, post, videos

Mid-Day Buzzers –Theratechnologies Inc. (THERF), Roche Holding Ltd. (RHHBY), Anavex Life Sciences Corp (AVXL), Federal Home Loan Mortgage Corp (FMCC)

“The market was short going into the Iran agreement, but the bears did not get the selloff they were hoping, so we’re going back up,” said Scott Shelton, commodities specialist and crude broker with ICAP in Durham, North Carolina.

Theratechnologies Inc. (OTCMKTS:THERF)at recent check, traded 288,377 shares in the recent trading session and the average volume of the stock remained 57,056 shares. The 52 week range of the stock remained $0.29- $1.80. The stock showed a positive movement of +0.08% and was recently trading at $1.68. The market capitalization of the stock remained 97.62M.Theratechnologies Inc. (THERF)specialty pharmaceutical company, addresses unmet medical needs in metabolic disorders. The company’s lead product is EGRIFTA (tesamorelin for injection), an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in the United States. It also focuses on commercializing EGRIFTA in Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, Thailand, and certain central Asian countries. The company was founded in 1993 and is headquartered in Montreal, Canada.

Why Should Investors Buy THERFAfter The Recent Gain? Just Go Here and Find Out

Roche Holding Ltd. (OTCMKTS:RHHBY)gained volume of 431,538 shares, while the average volume remained 1.60 million shares. The stock advanced+0.09% to $36.77. The EPS of the stock over the last 12 months remained 1.44. Roche Holding AG (RHHBY)declared that in the IMvigor 210 study, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) shrank tumors (objective response rate; ORR; the primary endpoint of this Phase II study) in people with locally advanced or metastatic urothelial bladder cancer (UBC) who had progressed on initial treatment (second-line or later). High amounts of PD-L1 (Programmed Death Ligand-1) expression by a person’s cancer correlated with increased response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab.

Will RHHBY Continue To Move Higher? Find Out Here

Anavex Life Sciences Corp (OTCMKTS:AVXL) gained volume of 1.07 million shares and the average volume of the stock remained 1.97 million shares. The 52 week range of the stock remained $0.15- $0.56 and today’s day range was $0.51- $0.54. The stock opened the session at $0.54 but then moved to $0.519, at recent check. At that price, the stock was showing a negative performance of -0.009%.Anavex Life Sciences Corp. (AVXL)a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer’s disease.

Why Should Investors Buy AVXL After the Recent Fall? Just Go Here and Find Out

Federal Home Loan Mortgage Corp (OTCBB:FMCC) so far this trade, showed that 627,581 shares were exchanged versus the average volume of 1.60 million shares. The stock began today’s trade at $2.11 and was recently trading at $2.14, escalating+0.05%. The market capitalization after this change moved to 1.39B. Federal Home Loan Mortgage Corporation (FMCC)priced its first offering of Structured Pass-Through Certificates (K Certificates) which are backed exclusively by fixed-rate multifamily mortgages with 12-20-year terms. The company expects to issue approximately $455 million in K Certificates (K-1501 Certificates), which are expected to settle on or about July 22, 2015. This is the company’s thirteenth K Certificates offering this year.

For How Long FMCC will Fight for Profitability? Read This Trend Analysis report